Skip to main content

Table 3 Multivariate analysis of composite outcome in patients with AAV

From: Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis

  P value Hazard ratio 95 % confidence interval
Model A    
 Age 0.69 0.99 0.96–1.02
 Gender (male vs. female) 0.32 1.44 0.71–2.91
 Hemoglobin (≤9 g/dl vs. >9 g/dl) 0.31 1.47 0.70–3.11
 Urinary protein (per g/24 hour) 0.02 1.29 1.05–1.58
 Plasma CFH levels (per 50 μg/ml increase) 0.03 0.85 0.73–0.98
Model B    
 Age 0.72 0.99 0.96–1.03
 Gender (male vs. female) 0.36 1.39 0.69–2.82
 Total crescents (%) (>50 % vs. ≤50 %) 0.26 1.69 0.68–4.17
 Urinary protein (per g/24 hour) 0.09 1.21 0.97–1.52
 Plasma CFH levels (per 50 μg/ml increase) 0.03 0.85 0.73–0.98
Model C    
 Age 0.31 1.02 0.99–1.05
 Gender (male vs. female) 0.75 1.12 0.55–2.29
 Initial serum creatinine (per mg/dl) <0.001 1.24 1.12–1.36
 Urinary protein (per g/24 hour) 0.002 1.34 1.12–1.62
 Plasma CFH levels (per 50 μg/ml increase) 0.57 0.96 0.83–1.11
  1. AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis, CFH complement factor H